Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.10+0.15 (+3.03%)
At close: 04:00PM EDT
5.09 -0.01 (-0.20%)
After hours: 06:16PM EDT
Advertisement

Aeterna Zentaris Inc.

315 Sigma Drive
Summerville, SC 29486
United States
843 900 3223
https://www.zentaris.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Klaus Paulini Ph.D.Pres, CEO & Exec. Director537.03kN/AN/A
Dr. Nicola Ammer M.D.Chief Medical Officer & Sr. VP of Clinical Devel.235.98kN/AN/A
Dr. Matthias GerlachSr. VP Manufacturing & Supply Chain258.6kN/AN/A
Mr. Giuliano La FrattaSr. VP of Fin. & CFON/AN/AN/A
Dr. Michael TeifelSr. VP of Non-Clinical Devel. & Chief Scientific OfficerN/AN/AN/A
Dr. Eckhard G. Guenther Ph.D.Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS GermanyN/AN/AN/A
Ms. Amélie MétivierAssistant Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Corporate Governance

Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement